Table 1.

Lapatinib concentrations that achieve IC50 and the corresponding levels of HER-2 and EGFR expression as measured by ELISA

Cell lineIC50 (SE), ╬╝mol/LHER-2 (SE), ng/mgEGFR (SE), ng/mg
UACC8120.010 (0.007)436 (33)25 (5.3)
MDA-MB-1750.012 (0.011)20 (3.3)3.8 (0.4)
SUM1900.018 (0.008)396 (29)3.1 (0.6)
BT4740.022 (0.020)530 (48)7.3 (0.7)
SK-BR-30.037 (0.031)913 (114)38 (7.4)
SUM2250.083 (0.081)1,161 (177)51 (9.1)
UACC8930.433 (0.076)577 (77)14 (3.2)
MDA-MB-3610.989 (0.222)211 (25)6.6 (1.2)
EFM192A1.1 (0.1)115 (22)1.0 (1.0)
T47D1.9 (1.4)11 (2.9)31 (8.0)
CAL511.2 (0.8)7.1 (1.4)11 (0.3)
MDA-MB-4533.9 (1.2)108 (18)1.3 (0.4)
EFM194.6 (1.7)22 (2.3)0.8 (0.2)
MDA-MB-4684.7 (1.6)0.1 (0.1)908 (73)
KPL15.4 (0.5)8.4 (1.4)3.2 (0.4)
MDA-MB-1576.3 (3.6)4.3 (1.2)59 (13)
MCF-77.7 (0.9)4.7 (1.6)2.7 (0.6)
CAMA18.3 (0.8)18 (3.1)3.2 (0.8)
MDA-MB-4358.5 (1.3)2.2 (0.8)4.4 (0.8)
BT209.8 (0.4)36 (9.1)295 (36)
ZR-75-19.9 (2.3)40 (4.5)8.3 (3.5)
MDA-MB-23118.6 (9.8)5.2 (1.9)58 (2.5)